Hypersensitivity to the active substances or to any of the excipients listed in Description.
Concomitant use with ACE inhibitors (see Precautions and Interactions). Entresto must not be administered until 36 hours after discontinuing ACE inhibitor therapy.
Known history of angioedema related to previous ACE inhibitor or ARB therapy (see Precautions).
Hereditary or idiopathic angioedema (see Precautions).
Concomitant use with aliskiren-containing medicinal products in patients with diabetes mellitus or in patients with renal impairment (eGFR <60 mL/min/1.73 m2) (see Precautions and Interactions).
Severe hepatic impairment, biliary cirrhosis and cholestasis (see Dosage & Administration).
Second and third trimester of pregnancy (see Use in Pregnancy & Lactation).